

23 February 2009

Acitretin, Bezafibrate, Diazepam and Disulfiram proposal approved

PHARMAC is pleased to announce the approval of a supply agreement with Actavis Australia Ltd for the supply of acitretin (Neotigason), bezafibrate (Bezalip Retard), diazepam (Stesolid) and disulfiram (Antabuse).

Summary of the decision

The subsidies and price for Neotigason, Bezalip Retard, and Stesolid will change in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 April 2009 as follows:

Chemical	Presentation	Brand	Pack size	Current price and subsidy	New price and subsidy
Acitretin	Cap 10 mg	Neotigason	100	\$94.75	\$75.80
Acitretin	Cap 25 mg	Neotigason	100	\$203.70	\$162.96
Bezafibrate	Tab long-acting 400 mg	Bezalip Retard	30	\$7.60	\$5.70
Diazepam	Rectal tube 5 mg	Stesolid	5	\$27.83	\$25.05
Diazepam	Rectal tube 10 mg	Stesolid	5	\$33.89	\$30.50
Disulfiram	Tab 200 mg	Antabuse	100	\$24.30	\$24.30

Neotigason and Bezalip Retard will have subsidy and delisting protection until 30 June 2012.

If you have any queries about this funding decision you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

What feedback was received?

No feedback was received in relation this proposal.